Journal of Cardiovascular Development and Disease

Journal Browser

► Journal Browser

Special Issue Editors

Prof. Dr. Felix B. Engel

Department Nephropathology, Institute of Patholology, Friedrich-Alexander-Universität Erlangen-Nürnberg, D-97054 Erlangen, Germany
Interests: heart; skeletal muscle; 3D bioprinting; electroconductive materials; cancer biology; kidney
Special Issues, Collections and Topics in MDPI journals

Dr. Ching-Ling (Ellen) Lien

E-Mail Website
Guest Editor

Department of Biochemistry & Molecular Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
Interests: zebrafish heart regeneration; coronary vessel development and re-vascularization; cardiac lymphatic vessel development; lymphangiogenesis

Special Issue Information

Dear Colleagues,

We are celebrating the 10th anniversary of the section “Cardiac Development and Regeneration” of the Journal of Cardiovascular Development and Disease with a Special Issue focusing on the advances in cardiac regeneration, including relevant discoveries in heart development during the last 10 years.

We would like to take this opportunity to thank our readers, authors, peer reviewers, editors, journal staff, and all other people that have contributed to the success of the Journal of Cardiovascular Development and Disease.

In the last 10 years, major advances have been made in understanding heart development and in identifying potential therapeutic strategies to treat heart diseases. Examples include the identification of pdgfrb+ cells regulating coronary vessel development and revascularization during heart regeneration, the establishment of cardiac organoids, 3D bioprinting of a four-chambered heart, understanding the nuclear MTOC in cardiomyocytes, modRNA-based heart therapies, and utilizing the Hippo pathway for heart regeneration based on cardiomyocyte proliferation. The purpose of this Special Issue is to review and comment on these and similar advances and to present novel related findings.

It is a real pleasure to serve as guest editors of this Special Issue. We invite you to contribute original research manuscripts, short communications, up-to-date review articles, and commentaries on a trendy or hot topic for peer-review and possible publication.

Prof. Dr. Felix B. Engel
Dr. Ching-Ling (Ellen) Lien
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Cardiovascular Development and Disease is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

cardiomyocyte proliferation
cardiac tissue engineering
3D bioprinting
vascular regeneration
vascular tissue engineering
3D bioprinting
cardiac organoids
hiPSC-differentiation
injectable materials

Published Papers (2 papers)

Download All Papers

Research

Jump to: Review

19 pages, 7552 KiB

Open AccessArticle

Differential Development of the Chordae Tendineae and Anterior Leaflet of the Bovine Mitral Valve

by Meghan Martin, Chih-Ying Chen, Timothy McCowan and Sarah Wells

J. Cardiovasc. Dev. Dis. 2024, 11(4), 106; https://doi.org/10.3390/jcdd11040106 - 29 Mar 2024

Viewed by 755

Abstract

There is increasing evidence that some adult mitral valve pathologies may have developmental origins involving errors in cell signaling and protein deposition during valvulogenesis. While early and late gestational stages are well-documented in zebrafish, chicks, and small mammalian models, longitudinal studies in large mammals with a similar gestational period to humans are lacking. Further, the mechanism of chordae tendineae formation and multiplication remains unclear. The current study presents a comprehensive examination of mitral anterior leaflet and chordae tendineae development in a bovine model (a large mammal with the same gestational period as humans). Remarkably distinct from small mammals, bovine development displayed early branched chordae, with increasing attachments only until birth, while the anterior leaflet grew both during gestation and postnatally. Chordae also exhibited accelerated collagen deposition, maturation, and crimp development during gestation. These findings suggest that the bovine anterior leaflet and chordae tendineae possess unique processes of development despite being a continuous collagenous structure and could provide greater insight into human valve development. Full article

(This article belongs to the Special Issue 10th Anniversary of JCDD—'Cardiac Development and Regeneration' Section — from Development to Regeneration)

► Show Figures

Figure 1

Review

Jump to: Research

14 pages, 953 KiB

Open AccessReview

Cell-Specific mRNA Therapeutics for Cardiovascular Diseases and Regeneration

by Raj Kishore and Ajit Magadum

J. Cardiovasc. Dev. Dis. 2024, 11(2), 38; https://doi.org/10.3390/jcdd11020038 - 26 Jan 2024

Viewed by 2080

Abstract

Cardiovascular diseases (CVDs) represent a significant global health burden, demanding innovative therapeutic approaches. In recent years, mRNA therapeutics have emerged as a promising strategy to combat CVDs effectively. Unlike conventional small-molecule drugs, mRNA therapeutics enable the direct modulation of cellular functions by delivering specific mRNA molecules to target cells. This approach offers unprecedented advantages, including the ability to harness endogenous cellular machinery for protein synthesis, thus allowing precise control over gene expression without insertion into the genome. This review summarizes the current status of the potential of cell-specific mRNA therapeutics in the context of cardiovascular diseases. First, it outlines the challenges associated with traditional CVD treatments and emphasizes the need for targeted therapies. Subsequently, it elucidates the underlying principles of mRNA therapeutics and the development of advanced delivery systems to ensure cell-specificity and enhanced efficacy. Notably, innovative delivery methods such as lipid nanoparticles and exosomes have shown promise in improving the targeted delivery of mRNA to cardiac cells, activated fibroblasts, and other relevant cell types. Furthermore, the review highlights the diverse applications of cell-specific mRNA therapeutics in addressing various aspects of cardiovascular diseases, including atherosclerosis, myocardial infarction, heart failure, and arrhythmias. By modulating key regulatory genes involved in cardiomyocyte proliferation, inflammation, angiogenesis, tissue repair, and cell survival, mRNA therapeutics hold the potential to intervene at multiple stages of CVD pathogenesis. Despite its immense potential, this abstract acknowledges the challenges in translating cell-specific mRNA therapeutics from preclinical studies to clinical applications like off-target effects and delivery. In conclusion, cell-specific mRNA therapeutics have emerged as a revolutionary gene therapy approach for CVD, offering targeted interventions with the potential to significantly improve patient outcomes. Full article

(This article belongs to the Special Issue 10th Anniversary of JCDD—'Cardiac Development and Regeneration' Section — from Development to Regeneration)

► Show Figures